Display options
Cite
Monteith TS, Goadsby PJ. Acute migraine therapy: new drugs and new approaches. Curr Treat Options Neurol. 2011;13(1):1-14doi: 10.1007/s11940-010-0105-6.
Monteith, T. S., & Goadsby, P. J. (2011). Acute migraine therapy: new drugs and new approaches. Current treatment options in neurology, 13(1), 1-14. https://doi.org/10.1007/s11940-010-0105-6
Monteith, Teshamae S, and Goadsby, Peter J. "Acute migraine therapy: new drugs and new approaches." Current treatment options in neurology vol. 13,1 (2011): 1-14. doi: https://doi.org/10.1007/s11940-010-0105-6
Monteith TS, Goadsby PJ. Acute migraine therapy: new drugs and new approaches. Curr Treat Options Neurol. 2011 Feb;13(1):1-14. doi: 10.1007/s11940-010-0105-6. PMID: 21110235; PMCID: PMC3016076.
Copy Download .nbib Format: NLM
Share it on

Curr Treat Options Neurol. 2011 Feb;13(1):1-14. doi: 10.1007/s11940-010-0105-6.

Acute migraine therapy: new drugs and new approaches.

Current treatment options in neurology

Teshamae S Monteith, Peter J Goadsby

Affiliations

  1. Department of Neurology, UCSF Headache Center, 1701 Divisadero Street, Suite 480, San Francisco, CA, 94115, USA.

PMID: 21110235 PMCID: PMC3016076 DOI: 10.1007/s11940-010-0105-6

Abstract

OPINION STATEMENT: The conceptual shift of our understanding of migraine from a vascular disorder to a brain disorder has dramatically altered the approach to the development of new medicines in the field. Current pharmacologic treatments of acute migraine consist of nonspecific and relatively specific agents. Migraine-specific drugs comprise two classes, the ergot alkaloid derivatives and the triptans, serotonin 5-HT(1B/1D) receptor agonists. The ergots, consisting of ergotamine and dihydroergotamine (DHE), are the oldest specific antimigraine drugs available and are considered relatively safe and effective. Ergotamine has been used less extensively because of its adverse effects; DHE is better tolerated. The triptan era, beginning in the 1990s, was a period of considerable change, although these medicines retained vasoconstrictor actions. New methods of delivering older drugs include orally inhaled DHE and the transdermal formulation of sumatriptan, both currently under study. Novel medicines being developed are targeted at neural sites of action. Serotonin 5-HT(1F) receptor agonists have proven effective in phase II studies and have no vascular actions. Calcitonin gene-related peptide (CGRP) receptor antagonists are another promising nonvasoconstrictor approach to treating acute migraine. Olcegepant (BIBN4096BS) and telcagepant (MK-0974) have been shown to be safe and effective in phase I, II, and (for telcagepant) phase III clinical trials. Other targets under investigation include glutamate (AMPA/kainate), TRPV1, prostanoid EP4, and nitric oxide synthase. With new neural targets and the potential for therapeutic advances, the next era of antimigraine medications is near.

References

  1. Nat Genet. 2010 Oct;42(10):869-73 - PubMed
  2. Pediatrics. 2000 Nov;106(5):989-97 - PubMed
  3. Cephalalgia. 2000 Dec;20(10):907-18 - PubMed
  4. Pain. 2006 Jan;120(1-2):170-181 - PubMed
  5. Neurology. 2006 Aug 8;67(3):497-9 - PubMed
  6. J Pharmacol Exp Ther. 2006 Dec;319(3):1096-103 - PubMed
  7. Eur J Pharmacol. 2004 Oct 1;500(1-3):315-30 - PubMed
  8. Neuroreport. 2001 Jun 13;12(8):1589-91 - PubMed
  9. Nat Clin Pract Neurol. 2007 Nov;3(11):610-9 - PubMed
  10. Eur J Neurol. 2009 Sep;16(9):968-81 - PubMed
  11. Cephalalgia. 2008 Aug;28(8):856-62 - PubMed
  12. Cephalalgia. 2000 Nov;20(9):765-86 - PubMed
  13. Lancet. 2008 Dec 20;372(9656):2115-23 - PubMed
  14. Ann Neurol. 1990 Aug;28(2):183-7 - PubMed
  15. Lancet. 1997 Feb 8;349(9049):401-2 - PubMed
  16. J Neurosci. 2006 Sep 13;26(37):9385-93 - PubMed
  17. Neurology. 1995 Mar;45(3 Pt 1):577-84 - PubMed
  18. Headache. 2009 Nov-Dec;49(10):1435-44 - PubMed
  19. Neuropeptides. 1999 Feb;33(1):41-6 - PubMed
  20. Nat Rev Drug Discov. 2007 May;6(5):357-72 - PubMed
  21. Ann Neurol. 1991 Jan;29(1):91-4 - PubMed
  22. Brain. 1996 Feb;119 ( Pt 1):249-56 - PubMed
  23. Expert Opin Investig Drugs. 2009 Jun;18(6):789-803 - PubMed
  24. Nat Med. 2002 Feb;8(2):136-42 - PubMed
  25. Lancet Neurol. 2010 Apr;9(4):373-80 - PubMed
  26. Br J Pharmacol. 2001 Nov;134(6):1296-302 - PubMed
  27. Headache. 2008 Oct;48(9):1326-36 - PubMed
  28. N Engl J Med. 2004 Mar 11;350(11):1104-10 - PubMed
  29. Histochem J. 1991 Apr;23(4):171-9 - PubMed
  30. Cephalalgia. 1988 Jun;8(2):83-91 - PubMed
  31. Lancet. 2001 Oct 13;358(9289):1230-4 - PubMed
  32. Cephalalgia. 2004 Jul;24(7):596-602 - PubMed
  33. Headache. 2006 Nov;46 Suppl 4:S171-81 - PubMed
  34. Br J Pharmacol. 2009 Jan;156(2):316-27 - PubMed
  35. Br J Pharmacol. 1999 May;127(2):468-72 - PubMed
  36. Naunyn Schmiedebergs Arch Pharmacol. 2009 Oct;380(4):311-25 - PubMed
  37. J Neurol. 1991;238 Suppl 1:S38-44 - PubMed
  38. Ann Neurol. 1988 Feb;23(2):193-6 - PubMed
  39. Brain. 2008 Aug;131(Pt 8):2192-200 - PubMed
  40. JAMA. 2007 Apr 4;297(13):1443-54 - PubMed
  41. Brain Res. 1992 Dec 4;597(2):321-30 - PubMed
  42. Neuroscience. 1999;90(4):1371-6 - PubMed
  43. Br J Pharmacol. 2009 Jun;157(3):464-73 - PubMed
  44. Circ Res. 1992 Jun;70(6):1313-9 - PubMed
  45. N Engl J Med. 2002 Jan 24;346(4):257-70 - PubMed
  46. Lancet Neurol. 2009 Aug;8(8):718-23 - PubMed
  47. Neurosci Lett. 2002 Sep 27;330(3):223-6 - PubMed
  48. Clin Neurophysiol. 2000 Jun;111(6):1124-9 - PubMed
  49. Mol Interv. 2005 Oct;5(5):304-11 - PubMed
  50. Brain. 2005 Apr;128(Pt 4):932-9 - PubMed
  51. Brain. 2010 Aug;133(Pt 8):2475-88 - PubMed
  52. CNS Drugs. 2007;21(1):73-82 - PubMed
  53. Pain. 2004 Aug;110(3):675-680 - PubMed
  54. Trends Pharmacol Sci. 1994 May;15(5):149-53 - PubMed
  55. Neurosci Lett. 1999 May 14;266(3):173-6 - PubMed
  56. J Neurol Sci. 1996 Jun;138(1-2):60-5 - PubMed

Publication Types